Kilitch Drugs Q1 FY27 Results (NSE: KILITCH)
Signal: Growth decelerated
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹44.88 Cr | 4.0% | -49.9% |
| EBIT | ₹4.74 Cr | -4.8% | |
| Net profit | ₹2.91 Cr | -4.0% | |
| EPS | ₹0.83 | -55.9% | |
| EBIT margin | 13% |
P&L walk
Consolidated revenue increased 4.0% YoY to ₹4,487.89 lakh, while EBITDA was broadly flat at ₹583 lakh and PAT declined 4.0% to ₹291.30 lakh; the key pressure was the ₹94.56 lakh non-controlling-interest loss and a sharp sequential normalization from Q4FY26.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.